XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 44.7

Change

+0.97 (+2.22)%

Market Cap

N/A

Volume

0.05M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-21 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+2.32 (+1.66%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

+1.16 (+1.74%)

USD 2.66B
FXH First Trust Health Care AlphaD..

+1.54 (+1.42%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

+1.95 (+2.11%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.57 (+2.60%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.88 (+2.83%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+2.59 (+2.69%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+1.15 (+3.91%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+1.37 (+2.27%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.63 (+2.91%)

USD 8.55M

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A
MSSS Northern Lights Fund Trus.. 10.12 % 0.00 %

+0.44 (+1.56%)

USD 0.11B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.98% 67% D+ 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.98% 67% D+ 67% D+
Trailing 12 Months  
Capital Gain 6.28% 71% C- 49% F
Dividend Return 1.61% 100% F 26% F
Total Return 7.89% 71% C- 42% F
Trailing 5 Years  
Capital Gain -5.36% 19% F 43% F
Dividend Return 5.44% 68% D+ 15% F
Total Return 0.08% 24% F 28% F
Average Annual (5 Year Horizon)  
Capital Gain -1.68% 19% F 25% F
Dividend Return -0.93% 19% F 17% F
Total Return 0.74% 68% D+ 19% F
Risk Return Profile  
Volatility (Standard Deviation) 15.93% 67% D+ 64% D
Risk Adjusted Return -5.85% 14% F 17% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.